<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687593</url>
  </required_header>
  <id_info>
    <org_study_id>17-4042-10</org_study_id>
    <nct_id>NCT03687593</nct_id>
  </id_info>
  <brief_title>Safety and Performance Using Legion™ CR Oxinium and CoCr Femoral Implants Combined With Legion™/Genesis™ II XLPE High Flex Tibial Inserts</brief_title>
  <acronym>Legion Oxinium</acronym>
  <official_title>Safety and Performance of Primary Total Knee Arthroplasty Using Legion™ CR Oxinium and CoCr Femoral Implants Combined With Legion™/Genesis™ II XLPE High Flex Tibial Inserts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to collect data on patients that had the Legion CR Oxinium&#xD;
      and CoCr Femoral Implant and the Legion/Genesis II XLPE High Flex Tibial Inserts implanted in&#xD;
      the past. Smith &amp; Nephew will evaluate the safety and performance of these implants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 30, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Implant survival 10 years postoperatively</measure>
    <time_frame>10 years post-op</time_frame>
  </primary_outcome>
  <enrollment type="Actual">126</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Legion™ CR Oxinium and CoCr Femoral Implants combined with Legion™/Genesis™ II XLPE High Flex Tibial Inserts</intervention_name>
    <description>Single arm study, all subjects received the Legion™ CR Femoral Oxinium and CoCr Implant with Legion™/Genesis™ II XLPE Hi-flex Tibial Insert</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Investigators will screen all subjects who underwent TKA with the LEGION™ CR Oxinium and&#xD;
        CoCR Femoral Implants&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject received primary TKA with the Legion™ CR Femoral Implant (either Oxinium or&#xD;
             CoCr) with Legion™/Genesis™ II XLPE Hi-flex Tibial Insert, due to degenerative joint&#xD;
             disease (primary diagnosis of osteoarthritis, post-traumatic arthritis, degenerative&#xD;
             arthritis, or rheumatoid arthritis).&#xD;
&#xD;
          2. Subject received primary TKA between 24 and 66 months prior to the time of consent.&#xD;
&#xD;
          3. Subject agrees to consent and to follow the study visit schedule (as defined in the&#xD;
             study protocol and informed consent form) by signing the IRB/EC approved informed&#xD;
             consent form.&#xD;
&#xD;
          4. Subject must be available through ten (10) years postoperative follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject had Body Mass Index (BMI) &gt; 40 at time of surgery.&#xD;
&#xD;
          2. Subject received the Legion™ CR Femoral Implant with Legion™/Genesis™ II XLPE Hi-flex&#xD;
             Tibial Insert as a revision surgery.&#xD;
&#xD;
          3. Subject has a condition that may interfere with the TKA survival or outcome (e.g.&#xD;
             Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled&#xD;
             diabetes, moderate to severe renal insufficiency or neuromuscular disease).&#xD;
&#xD;
          4. Subject has a known allergy to one or more of its components of the study device.&#xD;
&#xD;
          5. Subject, in the opinion of the Principal Investigator (PI), has an emotional or&#xD;
             neurological condition that would pre-empt their ability or willingness to participate&#xD;
             in the study including mental illness, mental retardation, drug or alcohol abuse.&#xD;
&#xD;
          6. Subject is entered in another drug, biologic, or device study or has been treated with&#xD;
             an investigational product in the past 30 days.&#xD;
&#xD;
          7. Subject is known to be at risk for loss to follow-up, or failure to return for&#xD;
             scheduled visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachael Winter</last_name>
    <role>Study Director</role>
    <affiliation>Smith &amp; Nephew, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allina Health Systems</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ROC Foundation</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawkins Foundation</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Appalachian Orthopedic Associates</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

